• SKIP TO CONTENT
  • SKIP NAVIGATION
  • Patient Resources
    • COVID-19 Patient Resource Center
    • Clinical Trials
    • Search Clinical Trials
    • Patient Notification System
    • What is Clinical Research?
    • Volunteering for a Clinical Trial
    • Understanding Informed Consent
    • Useful Resources
    • FDA Approved Drugs
  • Professional Resources
    • Research Center Profiles
    • Clinical Trial Listings
    • Market Research
    • FDA Approved Drugs
    • Training Guides
    • Books
    • eLearning
    • Events
    • Newsletters
    • JobWatch
    • White Papers
    • Patient Education
    • SOPs
    • eCFR and Guidances
  • White Papers
  • Trial Listings
  • Advertise
  • COVID-19
  • iConnect
  • Sign In
  • Create Account
  • Sign Out
  • My Account
Home » Directories » FDA Approved Drugs » Dupixent (dupilumab)

AND
  • A
  • B
  • C
  • D
  • E
  • F
  • G
  • H
  • I
  • J
  • K
  • L
  • M
  • N
  • O
  • P
  • Q
  • R
  • S
  • T
  • U
  • V
  • W
  • X
  • Y
  • Z

Dupixent (dupilumab)

  • Profile

Profile

Contact Information

Currently Enrolling Trials

    Show More

    General Information

    Dupixent (dupilumab) is a fully-human monoclonal antibody which inhibits the overactive signaling of interleukin-4 (IL-4) and interleukin-13 (IL-13), two key proteins that contribute to inflammation. 

    Dupixent is specifically indicated for use with other medicines to treat chronic rhinosinusitis with nasal polyposis (CRSwNP) in adults whose disease is not controlled. 

    Dupixent is supplied as an injection for subcutaneous administration.  The recommended dose of Dupixent for adult patients is 300 mg given every other week.

    Clinical Results

    FDA Approval

    The FDA approval of Dupixent for chronic rhinosinusitis with nasal polyposis in adults was based on two pivotal trials (the 24-week SINUS-24 and 52-week SINUS-52) that are part of the Phase 3 LIBERTY clinical trial program. These trials evaluated Dupixent 300 mg every two weeks with standard-of-care mometasone furoate nasal spray (MFNS) compared to placebo injection plus MFNS. In these trials, Dupixent significantly improved key disease measures and met all primary and secondary endpoints. At 24 weeks, patients treated with Dupixent achieved statistically significant improvements in all primary and secondary endpoints, including:

    • Co-primary endpoints:
      • 57% and 51% improvement in their nasal congestion/obstruction severity compared to a 19% and 15% improvement with placebo in SINUS-24 and SINUS-52, respectively (least squares [LS] mean change from baseline of -1.34 and -1.25 for Dupixent compared to -0.45 and -0.38 for placebo; difference between Dupixent and placebo: -0.89 and -0.87).
      • 33% and 27% reduction in their nasal polyps score compared to a 7% and 4% increase with placebo in SINUS-24 and SINUS-52, respectively (LS mean change from baseline of -1.89 and -1.71 for Dupixent compared to 0.17 and 0.10 for placebo; difference between Dupixent and placebo: -2.06 and -1.80).

    Side Effects

    Adverse effects associated with the use of Dupixent in adults with chronic rhinosinusitis with nasal polyposis may include, but are not limited to, the following:

    injection site reactions

    eosinophilia

    insomnia

    toothache

    gastritis

    arthralgia

    conjunctivitis

     

    Mechanism of Action

    Dupixent (dupilumab) is a human monoclonal IgG4 antibody that inhibits interleukin-4 (IL-4) and interleukin-13 (IL-13) signaling by specifically binding to the IL-4Rα subunit shared by the IL-4 and IL-13 receptor complexes. Dupilumab inhibits IL-4 signaling via the Type I receptor and both IL-4 and IL-13 signaling through the Type II receptor. Multiple cell types that express IL-4Rα (e.g., mast cells, eosinophils, macrophages, lymphocytes, epithelial cells, goblet cells) and inflammatory mediators (e.g., histamine, eicosanoids, leukotrienes, cytokines, chemokines) are involved in inflammation. Blocking IL-4Rα with dupilumab inhibits IL-4 and IL-13 cytokine-induced inflammatory responses, including the release of proinflammatory cytokines, chemokines, nitric oxide, and IgE.

    Additional Information

    For additional information regarding Dupixent or chronic rhinosinusitis with nasal polyposis in adults, please visit https://www.dupixent.com/crswnp

    Approval Date: 2019-06-01
    Company Name: Regeneron Pharmaceuticals and Sanofi
    Back to Listings

    Upcoming Events

    • 26Apr

      MAGI's Clinical Research vConference — Spring 2021

    • 06May

      The World of Post-COVID-19 Clinical Trials: How to Prepare for What’s Coming Next

    • 25May

      How Can the Accelerated Availability of Pfizer-BioNTech’s COVID-19 Vaccine be Replicated?

    Featured Products

    • Regenerative Medicine – Steps to Accelerate Development : PDF

      Regenerative Medicine: Steps to Accelerate Development

    • Clinical Trial Agreements — A Guide to Key Words and Phrases : PDF

      Clinical Trial Agreements: A Guide to Key Words and Phrases

    Featured Stories

    • Bottleneck-360x240.png

      Sites Face Trials Bottleneck After Pandemic, But Also Opportunities

    • AsktheExpertsBadge-360x240.png

      Ask the Experts: Genetic Research and IBC Oversight Requirements

    • Inspection-360x240.png

      Pandemic Caused 34 Percent Drop in FDA Investigator Inspections in Fiscal 2020

    • ImproveEfficiency-360x240.png

      Firm Fees, Coordinated Workflows Among Ways Sites Can Improve Efficiency

    Standard Operating Procedures for Risk-Based Monitoring of Clinical Trials

    The information you need to adapt your monitoring plan to changing times.

    Learn More Here
    • About Us
    • Contact Us
    • Privacy Policy
    • Do Not Sell My Personal Information

    Footer Logo

    300 N. Washington St., Suite 200, Falls Church, VA 22046, USA

    Phone 617.948.5100 – Toll free 866.219.3440

    Copyright © 2021. All Rights Reserved. Design, CMS, Hosting & Web Development :: ePublishing